Nov 29, 2023 / 02:00PM GMT
Joseph Michael Catanzaro - Piper Sandler & Co., Research Division - Director & Senior Biotech Analyst
Perfect. Great. Well, appreciate everybody joining us here on the second day of Piper Sandler's Annual Healthcare Conference. I'm Joe Catanzaro, one of Piper's biotech analysts. My real pleasure to kick off this session here with Gilead. Joining us is their CFO, Andy Dickinson.
Obviously, 25 minutes, a lot of time to run through things. But maybe, Andy, I could give you a minute or 2 to just give a quick rundown of Gilead, what you guys have been up to and what we have to look forward to in 2024.
Andrew D. Dickinson - Gilead Sciences, Inc. - Executive VP & CFO
Great. Yes. No, thanks. Thanks for having us. It's great to be here. Always fun to be here this time of the year. We've been up to a lot. I mean it's been an exciting 2023, and we have a lot teed up for 2024.
So in a snapshot, for those of you that don't know Gilead, we're the world's largest virology company. We have a thriving virology business that's growing, led by our
Gilead Sciences Inc at Piper Sandler Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot